Published

Considerations in assessing the abuse potential of psychedelics during drug development.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuropharmacology
Date: 2023-02-15
Source: PubMed
DOI: 10.1016/j.neuropharm.2022.109352
PubMed: 36455646

Authors

Calderon SN Bonson KR Reissig CJ Lloyd JM Galati S Chiapperino D

Watch author

Derived topics and classifications

psilocybin Receptor Pharmacology Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Considerations in assessing the abuse potential of psychedelics during drug development.2023-02-15

Related papers

Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.Journal of psychiatric research · 2026-10-01 Correlation of Ketamine and Classic Psychedelics with Pain-Related Neural Connectivity: A Scoping Review of Clinical Experiments on a Potential Therapeutic Target Concerning Ketamine and Classical Psychedelics Administration for Pain ReliefPsychedelic Medicine · 2026-09-14 Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-10-01 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-10-01 Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable predictionFrontiers in Pharmacology · 2026-09-30 Targeting the serotonin 1B receptor for the treatment of depression and anxiety.Expert opinion on therapeutic targets · 2026-09-28 Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-09-24 Preclinical Anxiolytic- and Antidepressant-like Effects of α,α-Trehalose, a Bioactive Compound Identified in Psilocybe cubensisMolecules · 2026-09-23